Compare Inovio Pharmaceuticals Inc (INO) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs SoFi Technologies Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while SoFi Technologies Inc trades at $17.37 (market cap $21.82B). The key difference: SoFi Technologies Inc is far larger — about 244.4× Inovio Pharmaceuticals Inc's market cap, and SoFi Technologies Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SOFI | |
|---|---|---|
Market Cap | $89.27M | $21.82B |
Sector | Health | Financials |
52-Week High | $2.87 | $32.21 |
52-Week Low | $1.05 | $15.15 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
SOFI Technologies trades at $17.07, down 1.22% with a bearish technical signal. The company shows strong revenue growth, reaching $3.61B in 2025 with consistent earnings beats, though net income declined to $481M. Analyst consensus is mixed with a $22.43 price target, while recent news highlights upcoming Q2 earnings and takeover speculation.
SOFI presents growth potential with 30% revenue guidance and digital platform expansion, but faces risks from negative operating cash flow and competitive pressures. The stock's current valuation at 38.4 P/E requires continued execution to justify upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
